PCV19 RESIDUAL DYSLIPIDEMIA ON SIMVASTATIN: POPULATION MODELING OF OPTIMAL LIPID VALUE ACHIEVEMENT WITH ADDED EXTENDED-RELEASE NIACIN VERSUS EZETIMIBE
Stanek E 1 , Charland S 2 1 None, Thorofare, NJ, USA, 2 School of Pharmacy, University of Colorado, Winter Park, CO, USA OBJECTIVE: To compare the population modeling effects of simvastatin alone, simvastatin plus ezetimibe and simvastatin plus extended-release niacin (ERN) on achievement of individual and combined optimal lipid values in untreated managed care patients with coronary heart disease (CHD) or risk equivalent (CHD/RE). METHODS: Patients with a baseline lipid panel between January 1, 2000 -December 31, 2001 , no concomitant dyslipidemia therapy, continuous eligibility for 24 months, and CHD or CHD/RE by diagnosis or procedure were analyzed from a 2.1 million record managed care database (HealthCore, Inc. Research Integrated Dataset). Patient-level lipids were assessed for achievement of guideline-defined optimal lipid values for LDL-C (<100 mg/dL), HDL-C (>40 mg/dL men; >50 mg/dL women), triglycerides (TG; <150 mg/dL), non-HDL-C (<130 mg/ dL), and combined LDL-C + HDL-C + TG at untreated baseline, after simvastatin 40 mg, after simvastatin + ezetimibe 10 mg, and after simvastatin + ERN 1 g and 2 g. Treatment effects were modeled based on product labeling, assuming additivity for sim-vastatin and ERN. Primary outcome measure was percentage of patients with nonoptimal values. RESULTS: Analysis included 20,948 patients: 49% female, mean (ϮSD) age 65 Ϯ 14 years, hypertension 62%, diabetes 34%. At untreated baseline, nonoptimal values occurred in 79% for LDL-C, 43% HDL-C, 42% TG, 77% nonHDL-C, and 92% for combined lipids. After modeled therapy, nonoptimal value frequencies were: simvastatin LDL-C 34%, HDL-C 14%, TG 34%, nonHDL-C 36%, and combined 69% (p < 0.05 vs baseline); simvastatin + ezetimibe LDL-C 21%, HDL-C 23%, TG 32%, nonHDL-C 31%, and combined 53% (p < 0.05 vs baseline, simvastatin); simvastatin + ERN 1 g and 2 g LDL-C 25% and 18%, HDL-C 0.2% and 0%, TG 30% and 22%, nonHDL-C 20% and 10%, and combined 46% and 36% [p < 0.05 vs baseline, simvastatin, simvastatin + ezetimibe (p = NS for TG at 1 g dose)]. CONCLU-SION: In this high-risk population, nonoptimal lipid values were very prevalent and persisted after modeled simvastatin 40 mg. Modeled simvastatin + ERN 1-2 g diminished residual dyslipidemia and nonoptimal lipid values more than simvastatin + ezetimibe.
PCV20 UPDATING THE RXRISK-V: CREATING A CROSSWALK BETWEEN VA AND FIRSTDATABANK THERAPEUTIC CATEGORIES
LaFleur J, Ghate S, Sauer B University of Utah, Salt Lake City, UT, USA OBJECTIVE: Co-morbidity indices based on drug utilization have been used to predict costs of care. The original RxRisk co-morbid disease index was based on United States (US) National Drug Code (NDC) numbers, and as such, needed to be updated at the NDC level for any change in manufacturer, repackager, or generic status, or with the introduction of each new molecular entity to the US market. The RxRisk-V was a modification of the original that used Veteran Affairs (VA) drug codes rather than NDC numbers to assign co-morbidity status for a set of diseases. Use of VA drug codes rather than NDCs simplifies the process of updating the tool. We undertook to create a crosswalk between VA drug codes and FirstDataBank (FDB) categories so the tool could be used with non-VA pharmacy data. METHODS: We obtained SAS code and disease category tables for the RxRisk-V. Clinical pharmacists reviewed the RxRisk-V disease categories and created an algorithm for mapping VA therapeutic categories to FDB specific drug therapeutic class categories. Pharmacists also updated disease categories to include drugs that would not have been updated in the RxRisk-V due to new therapeutic categories introduced since 1999. Generic name, brand name, and route of administration fields were used to specify which agents within each FDB therapeutic class were predictive of each RxRisk-V disease category. The SAS code for the RxRisk-V was modified to crosswalk between VA codes and non-VA pharmacy data. RESULTS: We successfully applied the crosswalk to a cohort of 19,458 patients from the RxAmerica database and generated co-morbidity scores. CONCLUSION: Using the RxRisk-V enables investigators to apply an updated co-morbid disease severity index to VA pharmacy data. We created a crosswalk to enable use with non-VA pharmacy data. Future work is needed to validate the tool with the crosswalk incorporated.
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